Evaxion Biotech's AI-Immunology™ Platform Shows Strong Validation in Multiple Clinical Trials

AI-Powered Cancer Vaccine Platform Shows Promise

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, has reported significant validation of its AI-Immunology™ platform in multiple clinical trials. The platform, designed to develop personalized cancer vaccines, has demonstrated a strong ability to predict effective vaccine targets, potentially revolutionizing cancer treatment 1

1

2

Clinical Trial Results

Evaxion has developed three personalized cancer vaccine candidates using its AI-Immunology™ platform:

1. EVX-01: Completed phase 1, currently in phase 2
2. EVX-02: Completed phase 1
3. EVX-03: IND-ready vaccine candidate

In all three clinical trials, a statistically significant correlation was observed between the AI-Immunology™ prediction scores and the immunological responses measured in patients. The most robust responses were generated by vaccine targets with the highest AI-Immunology™ prediction scores 1

1

2

Progression Free Survival Correlation

In one trial where it was assessed, a statistically significant correlation was demonstrated between AI-Immunology™ prediction scores and Progression Free Survival (PFS) in patients. This finding underscores the platform's ability to identify vaccine targets with meaningful clinical impact 1

1

2

AI-Immunology™ Platform

The AI-Immunology™ platform is a scalable and adaptable artificial intelligence technology at the forefront of vaccine discovery for infectious diseases and cancers. It integrates proprietary AI models PIONEER™, EDEN™, RAVEN™, and ObsERV™ to model the complexity of the patient's immune system 1

1

2

Key features of the platform include:

1. Identification of cancer vaccine targets (neoantigens)
2. Assignment of prediction scores for each target
3. Swift and unique identification, prediction, and design of vaccine candidates

Implications for Personalized Cancer Treatment

Christian Kanstrup, CEO of Evaxion, emphasized the importance of these findings: "The correlation between the platform's prediction score and clinical outcome is unique and provides very solid guidance for the further development of personalized cancer vaccines based upon AI-Immunology™" 1

1

2

Related Stories

Evaxion's AI-Designed Cancer Vaccine Shows Promising Results in Phase 2 Trial

Evaxion Biotech Reports Promising Results in Vaccine Development

Evaxion Biotech Expands Vaccine Development Collaboration with MSD

Biotech Companies IMUNON and Evaxion Report Q2 2024 Financial Results and Business Updates

Continuous Improvement through Data Generation

The ongoing generation of relevant clinical data allows for continuous refinement of AI-Immunology™, thereby broadening the commercial potential of the platform. This iterative process enables the application of constant learning loops, enhancing the platform's predictive capabilities 1

1

2

Evaxion's Pipeline

Based on the AI-Immunology™ platform, Evaxion has developed:

1. A clinical-stage oncology pipeline of novel personalized vaccines
2. A preclinical infectious disease pipeline targeting bacterial and viral diseases with high unmet medical needs 1

   1

   2

   2

As Evaxion continues to gather clinical data and refine its AI-Immunology™ platform, the company aims to transform patients' lives by providing innovative and targeted treatment options in the field of personalized cancer vaccines and beyond.